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INTRODUCTION
Melanoma (MM) is the human malignancy that has undergone the greatest increase in 
incidence during the last few decades. To improve prognosis, it is critical to identify patients 
bearing high risk of suffering MM, and as well as genetic factors of predisposition and 
progression. Ninety percent of melanomas are considered sporadic, and the main risk factors 
implicated are ultraviolet radiation (UVR) and the presence of melanocytic nevi [1–5]. 
Exposure of human skin to sunlight containing both A and B UVR leads to deleterious 
cutaneous effects, the most remarkable being skin cancer [6]. Currently the most widely 
used method of protection against UV-induced damage is the use of topical sunscreens, 
which act through physical particles enriched with chemical molecules that reflect and/or 
absorb UVR. A systemic photoprotective agent would have several advantages over topical 
protection, as this would provide more uniform, prolonged, and total body surface 
protection, independently of the specific properties of the creams, the amount applied, and 
other individual factors such as sweating or water bathing.
Polypodium Leucotomos (PL) is a tropical fern that has long been used for the treatment of 
inflammatory disorders by Native Americans [7]. Extracts of PL, topically applied or orally 
taken, have been shown to have a variety of potentially beneficial properties. Administration 
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of PL to mice decreases the degree of histological parameters of photoaging damage 
resulting from UVB radiation exposure and lowers the incidence of UVB radiation-induced 
non-MM skin cancers [8]. Furthermore, PL extract activates tumor suppressor p53, inhibits 
UV-induced Cox-2 expression, reduces inflammation, enhances the removal of UV-induced 
photoproducts, such as cyclobutane pyrimide dimers, as well as reduces oxidative DNA 
damage and decreased UV-induced mutagenesis [9]. Finally, oral administration of PL 
extracts to humans decreases ultraviolet radiation-induced skin damage [10, 11] as well as 
psoralen- UVA radiation-induced phototoxicity and pigmentation [10, 12] and, recently, also 
has shown to prevent UVA-induced common deletions and mitochondrial DNA damage 
(13).
Heritable alleles for MM susceptibility range from high-risk genes, high penetrance alleles 
that are rare, to low-risk genes, low-penetrance alleles that are rather ubiquitous. This has 
been captured in the adage “common variants (i.e., polymorphisms) cause common disease 
(ie, sporadic MM), whereas rare variants (i.e., mutations) cause rare disease (ie hereditary 
MM).” The high penetrance alleles can be responsible for rare familial clusters of MM, but, 
fortunately, they do not participate in common sporadic cases.
Low penetrance alleles are quite prevalent in the general population, but are not as closely 
associated with the ultimate development of MM. Thus, whereas more patients with MM 
have a combination of these low-risk allelic mutations, most patients with these variants will 
not ever develop MM.
The cyclin-dependent kinase (CDK) inhibitor 2A gene (CDKN2A) is the best-established 
high-risk locus for MM. It has been determined that, in aggregate, 25% to 50% of familial 
MM kindred are affected by a CDKN2A mutation. This prevalence increases as the number 
of affected cases increase in the index family. In smaller studies, up to 10% of patients with 
multiple primary MM (MPMs) have been identified to display a CDKN2A mutation. In a 
large population-based study, however, reported CDKN2A mutation rates are about 1% for 
the unselected MM patient and about 3% for individuals with MPM [14, 15]. Although most 
familial cases of MM are caused by mutations in CDKN2A, some families are affected by 
genetic mutations downstream of CDKN2A. Mutations in cyclin-dependent protein kinase 4 
(CDK4) have been identified in some MM kindreds [16].
Beyond genes known to confer a high degree of susceptibility to cutaneous MM, other genes 
have been proposed to confer moderate risk. Fair skin and red hair colour has been 
associated with increased MM risk. Specific variants in the Melanocortin 1 receptor (MC1R) 
gene produce variable quantity of the red/yellow pheomelanin pigment which induces 
oxidative cell-damage, instead of the brown to black eumelanin which is photoprotective. 
Depending on these MC1R variants, and other pigment track genes (OCA, TYR, …) the most 
common phenotype is that of individuals of blond or red hair, Fitzpatrick’s skin phototype I, 
tendency to sun-induced freckling, and reduced tanning response [17, 18]. Variants in MC1R 
are relatively common in the white population and have been proposed to confer low to 
moderate MM susceptibility risk [19, 20]. One large study noted a 2.2-fold increased in the 
relative odds of developing cutaneous MM among individuals with one “red hair” variant 
(RHV), and a 4.1-fold increased relative odds in those with two variants. Increased risk 
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remained unchanged for carriers who had non-RHV and darker skin. RHV of MC1R also 
have been demonstrated to increase the rate of MM in individuals who have CDKN2A 
mutations [21, 22]. More than 30 allelic variants of the human MC1R have been identified, 
mainly in Northern European populations and in Australia. The consequences of these 
variants on physiological function of the product of the MC1R gene have just begun to be 
elucidated. For example, it is known that R160W homozygote and R151C/D294H, R160W/
D294H compound heterozygote fail to couple to cAMP activation, show impaired tyrosinase 
activation in response to αMSH stimulation and display a pronounced sensitivity to UVR 
[23].
The aim of this study was to test the possible role of an oral PL extract to improve systemic 
photoprotection in patients at risk of skin cancer. The first goal was to further analyze the 
ability to decrease UV-induced erythema. A second aim was the study of the interaction 
among MC1R polymorphisms and CDKN2A status with the minimal erythematous dose 
(MED) and their influence in the response after oral PL.
PATIENTS AND METHODS
Participant selection
We included 61 patients belonging to the following groups: 25 patients with familial and/or 
multiple MM (2 or more first-degree relatives with MM and/or two or more MMs in the 
same patient), 20 patients with sporadic MM and 16 patients with atypical mole syndrome 
without history of MM.
Patients were included after they read and signed a written informed consent form approved 
by the ethical committee of Hospital Clinic de Barcelona, Barcelona, Spain. Exclusion 
criteria were history of abnormal photosensitivity (defined by any photo-induced dermatosis 
or demonstration of a decreased minimal erythemathous dose to UVB; lower than 100mJ/
cm2), or photosensitivity induced drugs intake, UVR (natural or artificial) exposure 6 weeks 
before the study.
Descriptive study
Patient phenotyping—Skin type of each individual was determined in accordance to 
Fitzpatrick classification (I to IV), eye colour was categorized as “brown”, “black”, “green” 
or “blue” and hair colour was recorded as “brown”, “black”, “blonde” or “red”. Number and 
clinical and dermoscopical description of nevi was studied.
Patient genotyping—Blood samples were taken from all patients. The PUREGENE 
DNA Isolation Kit (Gentra Systems, Minneapolis, MN, USA) was used to isolate genomic 
DNA from lymphocites according to the manufacturer's instructions.
Promoter (−34G>T variant), intronic (IVS2–105) and coding regions of the CDKN2A gene 
(exons 1α, 2 and 3 of the p16INK4A protein and exon 1β corresponding to p14ARF protein) 
were amplified by PCR using primers and conditions previously described [24]. MC1R was 
amplified using primers described by Chaudru et al.[25]. SSCP analysis was carried out. 
Samples with abnormal migration products were sequenced as follows: PCR products were 
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purified using the GFX™ PCR DNA and Gel Band purification kit (Amersham Biosciences) 
and automatically sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit 
(Applied Biosystems, Foster City, CA) and an ABI3100 automatic sequencer (Applied 
Biosystems).
UVR sensitivity assessment—UVB minimal erythematous dose (MED) was assessed 
in each patient by means of a Waldmann UV800 lamp as performed in The Fotobiology 
Unit of the Hospital Clinic, Barcelona. Normal skin on the central back of patients was 
irradiated in 6 consecutive increasing dose-exposure windows (doses of 0.02, 0.05, 0.07, 
0.10, 0.15 and 0.20 J/cm2) on a 2-cm2 area at 20 cm distance from the lamp (Fig 1). The 
UVB-MED was defined as the minimal dose of radiation per cm2 which induces confluent 
erythema at 24 hours with 4 sharp borders of the exposed skin site.
Intervention assay design—After basal MED assessment, all participants received the 
same oral dose of a commercial form of PL (120mg each capsule; Difur®, Industrial 
Farmaceutica Cantabria, SA, Madrid, Spain); 720 mg of oral PL in three doses, (240mg 
every 8hours) and 360 mg in a single dose, were administered one day and 3 hours 
respectively, before a second MED assessment (total dose of 1080mg).
Clinical evaluation of both basal and post-treatment MED were performed by 2 experienced 
dermatologists.
Statistical analysis
Descriptive analysis of the sample was performed, including percentages for categorical 
variables, and mean, minimum, maximum and standard deviation values for continuous 
variables. Comparisons of continuous variable means were performed using Student’s exact 
t test when variables followed a normal distribution. Comparisons of discrete variable means 
were performed using the Mann–Whitney non parametric test. Comparisons between 
categorical variables were performed with χ2 tests and Fisher corrections were performed 
when required. Categorical multivariable analysis was performed to evaluate independent 




Phenotyping: A total of 61 patients were included in the study belonging to the following 
groups: 20 (33.3%) sporadic MM, 25 (41.7%) familial MM and 16 (25%) dysplastic nevus 
syndrome. The mean age was 47.79±14.75 years with a minimum of 15yr and a maximum 
of 76yr. Gender distribution was 29 male (48.3%) and 31 female (51.7%). Individuals from 
our study population mainly exhibit a dark eyes and hair phenotype: 75.9% dark hair and 
63.8% brown eyes. However, the most frequent skin type was II (47.4%) followed by skin 
type III (36.8%). Nevertheless, a non-depreciating percentage of our patients showed at least 
one phenotypic risk factor: 56.1% of individuals showed fair skin pigmentation, 36.2% 
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green or blue eyes, 24.1% red or blonde hair (10.3% red hair) and 53.5% accumulated 
photodamage such as actinic lentigos (Table 1).
Study of mutations on the CDKN2A gene were performed in 37 individuals. Of these, 9 
(24.3%) were mutation carriers, all of them belonging to the familial melanoma group. From 
the familial MM patients, 9 (33%) were mutation carriers. Fifty five patients were studied 
for polymorphism in the MC1R gene of whom 17 (30.9%) were wild type (WT). Twenty 
seven patients were carriers of one functional variant, 9 patients were carriers of two 
functional variants and 2 patients were carriers of three functional variants of the MC1R 
gene. Three patients were carriers of two red hair variants in the MC1R. The distribution of 
variants on our sample is shown in Table 2.
Basal photosensitivity—The mean basal MED in overall population was 0.124 ± 0.04 
J/cm2, with a minimum of 0.07 and a maximum of 0.20 J/cm2. Interestingly, men and 
women presented differences in basal MED values. Women had a higher basal MED than 
men (0.14 vs 0.11 J/cm2), U=232.5, p<0.05. As well, a high percentage of patients with 
familiar MM had a higher basal MED value (≥0.15 J/cm2) than the rest of the patients 
(sporadic melanoma and dysplastic nevus syndrome), but this was not statistically 
significant. Nor differences in basal MED were found between patients with past history of 
MM (N=45); also, differences were not statistically significant when we compared with 
patients with dysplastic nevus syndrome without MM history (N=16),(0.127 J/cm2 vs 0.117 
J/cm2, U= 293; p=0.23). None of these depended of presence of actinic lentigos, hair colour, 
eye colour, or MC1R polymorphisms (Table 3).
Despite the lack of statistically significant associations between a lower basal MED value 
and having red hair variants (RHV), non RHV or wild type (WT) MC1R, we observed that 
patients with at least one RHV had a tendency to lower basal MED values.
Photosensitivity after treatment—The mean of MED after PL treatment was 0.161± 
0.047 J/cm2, with a minimum of 0.07 and a maximum of 0.3 J/cm2. Again, we found 
significant different MED values after PL depending on gender, with a higher post-PL MED 
in women than men (0.18 vs 0.14 J/cm2), U=286, p<0.05.
Importantly, oral PL treatment significantly increased the MED mean in all group 
patients (0.123 to 0.161 J/cm2, p<0.05).
We noted that patients without history of MM tended towards higher MED post PL value 
(≥0.15 J/cm2) than patients with MM (93.3% vs 77.8%), but this was not statistically 
significant. Also, we found no significant differences in MED values after PL treatment 
between patients with and without history of MM (0.167 vs 0.157 J/cm2, U=326.5, p=0.83). 
We did not observe differences depending on the presence of actinic lentigos, the hair 
colour, the eye colour, or MC1R variants.
The effect of PL in increasing the mean MED was similar in all patients, independently of 
the group (with vs without MM, patients with familial MM vs without familial MM). The 
treatment was effective in terms of increasing mean MED in all groups. Although not 
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significant, we noticed a stronger effect of PL on the MED of patients with familial MM 
compared to those with MM (U=273, p=0.06). Among the patients with familial MM, those 
exhibiting a mutated CDKN2A and/or polymorphisms in MC1R displayed larger differences 
in response to treatment with PL.
Of the 61 patients studied, 21 (35%) did not show any effect in MED value after orally 
administered PL, whereas an increase in the MED values was demonstrated in the other 40 
(65%) patients. The increased in the MED after PL was associated with dark eyes (χ2=4.67, 
p<0.05) (OR 4.47, CI 95% 1.22–16.34) and a lower basal MED value (χ2=6.90, p<0.05) 
(OR 4.59, CI 95% 1.23–7.47). Phenotypic characteristics of responders and non responders 
are shown in Table 4. Multivariable analysis adjusted for age and sex revealed dark eyes and 
a lower basal MED to be independent risk factors for increasing MED after treatment. In 
this way, having dark eyes and a higher sensibility to UVR may be predictors of a good 
response to PL.
DISCUSSION
This study demonstrates that oral administration of PL leads to a significant reduction of 
sensitivity to UVR in terms of increased UVB - MED values (p<0.05). This improvement in 
sensitivity to UVR could be observed in all the groups included in this study, that is patients 
with dysplastic nevus syndrome, patients with sporadic MM and patients with familial MM.
MM is the most devastating form of skin cancer. The steady increase in the incidence of 
MM and its resistance to chemotherapy, together with its high potential to metastasize, have 
emphasized the importance of its prevention. It is becoming clear that solar UVR is a main 
risk factor in the aetiology of MM [26] and its protection is the only primary prevention 
against MM development. Besides avoiding sun exposure, using a sunscreen is the most 
accepted photoprotection method in developed countries, and the preventive effect of using 
a sunscreen in non-MM skin cancer has often been suggested. However, there is still debate 
whether it provides adequate protection against MM and nevus induction. Inadequate 
sunscreen application has been found to be a common failing leading to deficient 
photoprotection [27, 28]. There is increasing evidence that a number of substances when 
taken orally exert a preventive effect against UV-induced skin damage without adverse 
effects. The mechanisms of action are highly varied, affecting diverse signaling pathways 
and resulting in an antioxidant, anti-inflammatory, and immunomodulatory activity [29]. A 
systemic photoprotective agent would have an advantage over topical protection, as this 
would provide uniform, total body surface protection. Besides, patients with familial 
melanoma have other risk factors, which represent the main burden of risk, such as 
mutations in CDKN2A gene. Certain allelic variants in MC1R gene, namely R151C, R160W 
and D294H, are strongly associated with red hair phenotype and increased melanoma 
susceptibility. Natural expression of two of these variants sensitizes melanocytes to the 
citotoxic effect of UV, and increases the burden of DNA damage and oxidative stress [30]. 
In this study, patients with red hair variants of MC1R had no statistically significant lower 
basal MED values than patients without red hair variants, but we found a trend to lower 
basal MED values in patients with at least one red hair polymorphism. It could be possible 
that the number of patients included in the study is insufficient to achieve statistical 
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significance. Moreover, patients with wild type MC1R had not higher basal MED values 
than patients with not red hair MC1R polymorphisms. Interestingly, a high percentage (56%) 
of our patients with familial melanoma, have a high basal MED value (MED≥0.15 J/cm2), 
and they did not bear MC1R polymorphisms or red hair polymorphisms. In these familial 
melanoma cases the risk is probably most associated to high penetrance genes like CDKN2A 
and less to low medium penetrance genes like MC1R or other genes related with fair skin. 
Despite of these findings, the exposition to RUVB is a modifying environmental factor that 
increases the risk of melanoma also in this context [31]. The results of this study are very 
promising and suggest that patients with familial melanoma can benefit their selves from 
orally PL as far as it reduces significantly sensitivity to RUVB in terms of increased MED 
UVB (p<0.005). Due to the intrinsic high predisposition of these patients, any positive 
intervention to reduce their risk is very positive. Also very interesting and promising is the 
fact that orally PL reduces significantly RUVB effect in patients with sporadic MM and 
patients with dysplastic nevus syndrome in which the effects of UVR are the main 
responsible in the melanoma genesis.
Analysis of the basal MED values by gender reveals that women had a higher basal MED 
value than men, which means a lower sensitivity to UVR. No other differences between 
groups were observed although patients with red hair polymorphisms in MC1R had lower 
basal MED values than patients without, but this was not statistically significant (Table 3). 
The same results were found when analysing MED values post treatment, women had 
statistically significant higher MED values post treatment than men.
We found that patients exhibiting a positive effect of PL had more frequently dark eyes and 
a lower basal MED. The multivariable analysis adjusting by age and sex showed that dark 
eyes and lower basal MED are independent factors to predict a better response to PL.
Therefore, we can conclude that dark-eye patients and patients with higher UVR sensibility 
(lower basal MED) would be the most benefited from oral PL treatment. Previous studies 
have demonstrated that a single dose of orally administered PL decreases UVR-induced 
damage of human skin [10, 11]. However, the present study pioneers the effect of orally 
administered PL in patients with high risk to develop MM. Our results are very promising 
and suggest the need to perform long-term follow-up and long term administration of PL 
studies in patients bearing high risk of developing MM.
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MED minimal erythematous dose
CDKN2A cyclin-dependent kinase (CDK) inhibitor 2A gene
MPMs multiple primary MM
MC1R Melanocortin 1 receptor
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Table 1
Distribution of studied variables in men and women.
Men Women Whole sample
N= 29 (48.3%) N= 32 (51.7%) N=61 (100%)
MM N= 8 (40%) N= 12 (60%) N=20 (33.3%)
Familial MM N= 13 (52%) N= 12 (48%) N=25 (41.7%)
Dysplastic nevus syndrome N= 8 (50%) N= 8 (50%) N=16 (25%)
Mean age 50.03y 45.75y 47.79y 0.261
Skin type I–II N= 15 (53.6%) N= 17 (58.6%) N=32 (56.1%) 0.701
Skin type III–IV N= 13 (46.4%) N= 12 (41.4%) N=25 (43.9%) 0.701
Dark hair N= 22 (78.6%) N= 22 (73.3%) N=44(75.9%) 0.641
Blond/Red hair N= 6 (21.4%) N= 8 (26.7%) N=14 (24.1%) 0.641
Dark eyes N= 20 (71.4%) N= 17 (56.7%) N= 37 (63.8%) 0.242
Clear eyes N= 8 (28.6%) N= 13 (43.3%) N=21 (36.2%) 0.242
Actinic lentigos (moderate-severe) N= 12 (42.9%) N= 18 (62.1%) N= 30 (52.6%) 0.146
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Table 2
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Table 3
Basal MED means comparison between groups
Group Basal MED mean U p
Lentigos (N=30) vs no lentigos (N=26) 0’123 vs 0’124 J/cm2 401 0’945
Dark eye color (N=37) vs light (N=21) 0’120 vs 0’128 J/cm2 348’5 0’486
Dark hair color (N=44) vs fair (N=14) 0’122 vs 0’123 J/cm2 308 1
MC1R polymorphisms yes (N=38) vs no (N=17) 0’120 vs 0’123 J/cm2 309 0’784
RH polymorphisms yes (N=19) vs no (N=36) 0’114 vs 0’125 J/cm2 297 0’398
Men (N=29) vs Women (N=32) 0’107 vs 0’140 J/cm2 232’5 <0’05
MM (N=45) vs no MM (N=16) 0’127 vs 0’116 J/cm2 293 0’238
CDKN2A (N=9) vs WT (N=28) 0’122 vs 0’118 J/cm2 302 0’795
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Table 4
Phenotypic characteristics of responders and non-responders.
SKIN TYPE HAIR COLOUR EYE COLOUR
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